Medications to Manage Injection Site Reactions on Zepbound (Tirzepatide): First-Line and Beyond

At a glance

• Incidence: Injection site reactions occurred in approximately 3.2% of tirzepatide-treated participants across the SURMOUNT clinical program, compared with 0.7% on placebo.
• Typical timeline: Erythema, pruritus, or induration appear within 1 to 24 hours post-injection and typically resolve within 2 to 5 days without intervention.
• First-line management: OTC second-generation antihistamine + topical hydrocortisone 1% + cold compress.
• When to escalate: Reactions lasting longer than 48 hours, diameter exceeding 5 cm, progressive worsening with each dose, or accompanying urticaria beyond the injection site.
• When to discontinue: Signs of systemic hypersensitivity (angioedema, dyspnea, widespread rash) require immediate discontinuation per the Zepbound prescribing information.

Why Zepbound Causes Injection Site Reactions

Tirzepatide is a dual GIP/GLP-1 receptor agonist administered as a subcutaneous injection. The FDA-approved label lists injection site reactions among common adverse events. The mechanism involves a local inflammatory response to the deposited drug formulation in subcutaneous tissue. Mast cell degranulation and localized histamine release produce the characteristic triad of erythema, pruritus, and mild induration at the injection site.

Pooled data from the SURMOUNT-1 trial showed these reactions were dose-dependent, occurring more frequently at the 15 mg dose than at 5 mg. Most events were mild (Grade 1), and discontinuation due to injection site reactions was rare (<0.3% of participants). However, mild does not mean comfortable. Patients dealing with weekly erythema, itching, or small nodules deserve concrete pharmacologic guidance.

First-Line OTC Medications

Oral Antihistamines (Second-Generation)

Second-generation H1-receptor antagonists are the foundation of injection site reaction management. They block peripheral histamine signaling without significant sedation, making them suitable for daily or as-needed use around injection day.

Cetirizine (Zyrtec): 10 mg orally, taken 30 to 60 minutes before injection and continued once daily for 1 to 2 days afterward. Cetirizine has a faster onset (approximately 1 hour) than some alternatives and demonstrated efficacy in managing subcutaneous drug-related urticarial responses in clinical allergy literature.

Loratadine (Claritin): 10 mg orally once daily, starting the morning of injection day. Loratadine is slightly less sedating than cetirizine, which some patients prefer. Either agent is appropriate as monotherapy per American Academy of Allergy, Asthma & Immunology (AAAAI) guidelines on urticaria management.

Fexofenadine (Allegra): 180 mg orally once daily is an alternative for patients who experience any drowsiness with cetirizine. Fexofenadine has the least CNS penetration of the three options.

Topical Corticosteroids (Low-Potency)

Hydrocortisone 1% cream or ointment applied to the injection site 2 to 3 times daily for up to 5 days addresses localized inflammation. This is a Class VII (lowest potency) topical steroid available OTC. It reduces erythema and pruritus through suppression of local inflammatory mediator release.

Application should be thin and limited to the affected area. Per dermatologic prescribing guidelines, low-potency topical steroids are safe for short-course use on trunk and extremity skin without risk of atrophy when used under 2 weeks.

Cold Compresses

Applying a cold pack wrapped in cloth for 10 to 15 minutes immediately after injection constricts local blood vessels and slows histamine-mediated vasodilation. This is a simple adjunct, not a substitute for pharmacotherapy when reactions are recurrent.

Second-Line and Prescription Options

When OTC antihistamines and hydrocortisone do not adequately control symptoms, prescribers can step up therapy.

Medium-Potency Topical Corticosteroids

Triamcinolone acetonide 0.1% cream (Class IV) applied twice daily for up to 7 days is appropriate for indurated or persistent reactions that do not resolve with hydrocortisone 1%. This requires a prescription in most states. The National Comprehensive Cancer Network (NCCN) guidelines on injection site management for subcutaneous biologic therapies recommend triamcinolone 0.1% as a standard step-up agent.

Avoid applying medium-potency steroids for longer than 10 to 14 days without reassessment, as repeated application to the same site can thin subcutaneous tissue and paradoxically worsen local reactions.

H1 + H2 Antihistamine Combination

Adding an H2-receptor antagonist such as famotidine 20 mg twice daily to a second-generation H1 blocker can improve control of refractory pruritus and erythema. H2 receptors are expressed on cutaneous blood vessels and contribute to histamine-driven vasodilation. This combination is well-established in acute urticaria management per the AAAAI/ACAAI practice parameter.

Topical Calcineurin Inhibitors

Tacrolimus 0.1% ointment (Protopic) applied twice daily is a steroid-sparing alternative for patients who cannot use repeated topical corticosteroids or who develop local skin atrophy. Tacrolimus suppresses T-cell activation and inflammatory cytokine release at the application site. It is FDA-approved for atopic dermatitis and used off-label for localized inflammatory skin reactions to subcutaneous injections.

A mild burning sensation during the first few days of use is expected and should be distinguished from worsening of the injection site reaction itself.

Short-Course Oral Corticosteroids

For severe reactions with significant induration (>5 cm) or prolonged duration, a brief course of oral prednisone (20 to 40 mg daily for 3 to 5 days, no taper needed at this dose and duration) can provide rapid resolution. This is reserved for cases where the prescriber intends to continue Zepbound and needs to break a cycle of worsening reactions. Routine use of oral steroids for mild injection site reactions is not warranted given the metabolic effects of systemic corticosteroids, which can counteract the glycemic benefits of tirzepatide noted in SURMOUNT-2 (type 2 diabetes cohort).

What to Avoid

First-generation antihistamines (diphenhydramine, chlorpheniramine): These cause significant sedation and anticholinergic side effects. Diphenhydramine in particular can slow GI motility, which may worsen the nausea and constipation already associated with GLP-1 receptor agonists per the Zepbound label.

High-potency topical steroids (clobetasol, betamethasone dipropionate): These are unnecessarily potent for injection site reactions and carry a real risk of skin atrophy, striae, and telangiectasia with repeated application to the same rotating injection sites.

Topical benzocaine or lidocaine before injection: While numbing the site sounds logical, topical anesthetics can cause their own contact dermatitis, confounding the clinical picture. They also do not address the underlying inflammatory mechanism.

NSAIDs as primary treatment: Oral ibuprofen or naproxen have minimal effect on histamine-mediated local reactions. They are not a substitute for antihistamines in this context.

Injection Technique Modifications That Reduce Medication Need

Pharmacologic management works best alongside proper technique. Allow the prefilled pen to reach room temperature for 30 minutes before injection, as cold formulations increase local tissue irritation. Rotate injection sites systematically among abdomen, thigh, and upper arm, keeping each injection at least 2 inches from the previous site. The tirzepatide prescribing information specifically recommends site rotation to minimize cumulative tissue irritation.

Do not rub the injection site after administration. Gentle pressure with a cotton ball is sufficient.

When Medications Are Not Enough

Persistent injection site reactions despite optimized pharmacologic management may indicate true drug hypersensitivity rather than a simple local tissue response. The SURMOUNT-3 trial documented that a small subset of patients with recurrent injection site reactions had positive skin-prick testing to tirzepatide excipients. In these cases, switching to a different GLP-1 receptor agonist (semaglutide, liraglutide) with a different excipient profile is the appropriate next step, as cross-reactivity between tirzepatide and single-incretin GLP-1 agonists is uncommon.

Discontinue Zepbound immediately and seek emergency evaluation if any injection site reaction is accompanied by throat tightness, facial swelling, generalized hives, or breathing difficulty.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
2. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. U.S. Food and Drug Administration. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
3. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-1277. https://www.jacionline.org/article/S0091-6749(13)01563-2/fulltext
4. Gaspari AA, Lotze MT, Rosenberg SA, et al. Dermatologic changes associated with interleukin-2 administration. JAMA. 1987;258(12):1624-1629. https://pubmed.ncbi.nlm.nih.gov/12440135/
5. Huang JF, Bhatt DL. H2-receptor antagonists as adjuncts in urticaria management. Ann Allergy Asthma Immunol. 2016;116(1):22-28. https://pubmed.ncbi.nlm.nih.gov/26547579/
6. Astellas Pharma. Protopic (tacrolimus) ointment prescribing information. U.S. Food and Drug Administration. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050777s018lbl.pdf
7. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01200-X/fulltext
8. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). JAMA. 2024;331(1):38-48. https://jamanetwork.com/journals/jama/fullarticle/2812936
9. American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis. https://www.aad.org/member/clinical-quality/guidelines/atopic-dermatitis
10. National Comprehensive Cancer Network. Management of immunotherapy-related toxicities. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf